{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-019840","form_type":"8-K","ticker":"DMAC","cik":"0001401040","company_name":"DiaMedica Therapeutics Inc.","filed_at":"2022-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.615612+00:00","generated_at":"2026-06-24T01:22:30.655357+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"DiaMedica identifies cause of DM199 clinical hold; plans FDA resubmission in Sep","bullets":["Clinical hold cause: DM199 protein bound to prior IV bag, reducing dose; new bag delivered higher dose, causing hypotension.","Will submit revised protocol to FDA in September requesting removal of clinical hold; FDA has 30 days to respond.","Cash and investments $38.4M as of June 30, 2022; cash runway into 2024.","R&D expenses $2.0M in Q2 2022 vs $2.2M Q2 2021; net cash used in ops $6.4M for six months.","REDUX CKD trial close-out ongoing; company maintains focus on acute ischemic stroke program."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-019840","json":"https://secwatch.observer/filing/0001437749-22-019840.json","markdown":"https://secwatch.observer/filing/0001437749-22-019840.md","text":"https://secwatch.observer/filing/0001437749-22-019840.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401040/000143774922019840/0001437749-22-019840-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401040/000143774922019840/dmtp20220810_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:22:30.655357+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}